Strategic trials Syntara is advancing multiple Phase 2 trials with lead candidate SNT-5505 in myelofibrosis and plans additional Phase 1c/2 studies in myelodysplastic syndrome, indicating ongoing clinical momentum and potential near-term milestones to align with partner and investor interest.

Collaborative programs The company is pursuing pan-LOX inhibitors for scar prevention and modification through a collaboration with Professor Fiona Wood and the University of Western Australia, plus SSAO/MAOB inhibitor development for neurodegenerative potential, creating cross-domain partner and licensing opportunities.

Bioheritage products Syntara markets bronchial therapies Bronchitol and Aridol with royalties, presenting an additional revenue stream and a potential pathway for customer cross-sell or clinical development partnerships leveraging existing product lines.

Financial and scale With a revenue range of 10–25 million and 51–200 employees, Syntara sits in a mid-size biotech segment that can be targeted for strategic collaborations, co-development deals, and potential equity financings as they progress through late-stage trials.

Strategic data Recent and upcoming data presentations at major hematology and ASH meetings signal opportunities to engage investors and pharma partners around interim phase results, expediting conversations for potential licensing, collaboration, or out-licensing of assets.